CTBp, CANDIDATE ORAL THERAPEUTIC AGENT AGAINST ULCERATIVE COLITIS (15094)
- 詳細技術說明
- None
- *Abstract
-
CTBp, CANDIDATE ORAL THERAPEUTIC AGENT AGAINST ULCERATIVE COLITIS (15094)
Features and Benefits Summary
Demonstrated physicochemical stability and oral immunogenicity.
Initial studies indicate a reduced dose frequency and amount as compared to current therapies.
Promising anti-inflammatory potential.
Demonstrated ability to enhance mucosal wound healing.
Potential for application in ulcerative colitis oral
*This Technology is available for licensing, further development, or industrial partnering*
Market Opportunity
Inflammatory boweldisease (consisting of ulcerative colitis (UC) and Crohn’s disease) ischaracterized by chronic inflammation in the gastrointestinal tract. In NorthAmerica alone, UC occurs in 249 out of 100,000 persons and this incidence inEurope is even higher, 505 out of 100,000 persons. Additionally, the risk ofcolorectal cancer, the second leading cause of cancer death in the UnitedStates, is significantly increased with inflammatory bowel disease. There is agreat demand for a compound that is cost-effective and shows great healingpotential in the colon. Additionally, as determined by experimentation, CTBpadministration requires a lower dose frequency and dosage amount compared tocurrent therapies. Further studies using CTBp will be necessary to determinepotential for human trial applications.
Technology
Cholera toxin Bsubunit (CTB) is a pleiotropic mucosal immunomodulatory protein that currentlyis used as an active component in an internationally licensed oral choleravaccine. However, CTB has not been tested for its immunomodulatory effect onthe gastrointestinal tract. Researchers at the University of Louisville havedeveloped a robust and rapid plant-based production system for a variant ofCTB, called CTBp, using a plant virus vector. Interestingly, researchers at UofLfound that CTBp exhibited more effective wound healing activity than the nativeform of CTB. Using a model of ulcerative colitis, it was demonstrated thatthrough oral administration of CTBp, there was a significant decrease indisease activity index, colon shrinkage and histopathological scores,indicating better therapeutic potential. This exciting vector was found for thefirst time to be a mucosal wound healing molecule. The studies performed by theUofL researchers demonstrate the ability of CTBp to enhance mucosal woundhealing, which further highlights its potential application in ulcerativecolitis oral immunotherapy.
Technology Status
- IP Status: ProvisionalPatent Application; Worldwide IP Protection Available.
- Development Status: Extensivestudy in laboratory models of disease.
- Fields of Use Available: All
Researchers:
- Dr. Nobuyuki Matoba
- Keegan Baldauf
- Joshua Royal
- 國家/地區
- 美國
